LRP1 and Alzheimer disease: Moreover, another study unveils compelling in vivo evidence that disrupting LRP1-mediated endocytosis shifts the APP processing towards non-amyloidogenic pathways, thereby reducing the amyloidogenic processing and decreasing extracellular Aβ and plaque formation in an AD mouse model.